ATE232545T1 - Rezeptor spezifische atrio-natriuretische peptide - Google Patents

Rezeptor spezifische atrio-natriuretische peptide

Info

Publication number
ATE232545T1
ATE232545T1 AT95901112T AT95901112T ATE232545T1 AT E232545 T1 ATE232545 T1 AT E232545T1 AT 95901112 T AT95901112 T AT 95901112T AT 95901112 T AT95901112 T AT 95901112T AT E232545 T1 ATE232545 T1 AT E232545T1
Authority
AT
Austria
Prior art keywords
receptor
human
atrio
natriuretic peptides
receptor specific
Prior art date
Application number
AT95901112T
Other languages
English (en)
Inventor
David Lowe
Brian C Cunningham
David Oare
Robert S Mcdowell
John Burnier
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE232545T1 publication Critical patent/ATE232545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT95901112T 1993-11-12 1994-11-04 Rezeptor spezifische atrio-natriuretische peptide ATE232545T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15299493A 1993-11-12 1993-11-12
PCT/US1994/012591 WO1995013296A1 (en) 1993-11-12 1994-11-04 Receptor specific atrial natriuretic peptides

Publications (1)

Publication Number Publication Date
ATE232545T1 true ATE232545T1 (de) 2003-02-15

Family

ID=22545344

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901112T ATE232545T1 (de) 1993-11-12 1994-11-04 Rezeptor spezifische atrio-natriuretische peptide

Country Status (10)

Country Link
EP (1) EP0728147B1 (de)
JP (1) JP3989535B2 (de)
AT (1) ATE232545T1 (de)
AU (1) AU1934995A (de)
CA (1) CA2174517C (de)
DE (1) DE69432123T2 (de)
DK (1) DK0728147T3 (de)
ES (1) ES2194895T3 (de)
PT (1) PT728147E (de)
WO (1) WO1995013296A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503256A (ja) * 1996-10-22 2001-03-13 ジェネンテック，インコーポレーテッド レセプター選択的ｂｎｐ
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
AU6820898A (en) * 1997-04-04 1998-10-30 Novo Nordisk A/S Natriuretic peptide derivatives
US6013630A (en) 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
US8580746B2 (en) 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
AU2007233116B2 (en) 2006-03-30 2013-05-09 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
AU2007233123A1 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2848411B2 (ja) * 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
EP0465097A3 (en) * 1990-06-26 1993-03-24 Merck & Co. Inc. Peptides having atrial natriuretic factor activity

Also Published As

Publication number Publication date
CA2174517A1 (en) 1995-05-18
DE69432123T2 (de) 2004-01-08
EP0728147A1 (de) 1996-08-28
DE69432123D1 (de) 2003-03-20
PT728147E (pt) 2003-06-30
ES2194895T3 (es) 2003-12-01
CA2174517C (en) 2007-01-02
AU1934995A (en) 1995-05-29
JPH09505049A (ja) 1997-05-20
JP3989535B2 (ja) 2007-10-10
DK0728147T3 (da) 2003-06-10
EP0728147B1 (de) 2003-02-12
WO1995013296A1 (en) 1995-05-18

Similar Documents

Publication Publication Date Title
DE69432123D1 (de) Rezeptor spezifische atrio-natriuretische peptide
FR2697525B1 (fr) Peptides de fusion ayant une activité de liaison à la streptavidine.
DE69833667D1 (de) Polynukleotid kodierend für ein polypeptid mit heparanase-aktivität und dessen expression in transduzierten zellen
EP0769554A3 (de) Menschliches CNP-Gen und Vorläuferprotein
ATE297202T1 (de) Verwendung von nichtimmununterdruckende verbindungen zur förderung von nervenregeneration
DE3851238D1 (de) Antikoagulierende Peptide.
AU6354198A (en) Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
CA2303344A1 (en) Improved stent configurations
EP0182372A3 (de) Faktor-VIII-gerinnende Polypeptide
BG102817A (en) Modulators of factor traf asociated with tnf-receptor, their preparation and application
ATE229542T1 (de) Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen
NO883731D0 (no) Isbrytende skip.
ES2104639T3 (es) Adnc para un peptido natriuretico de tipo c de rata, y proteina precursora.
AU4211989A (en) Atrial natriuretic peptide clearance inhibitors
ATE221537T1 (de) Neue (alpha-aminophosphino) peptide, verfahren zu ihrer herstellung und ihre therapeutische verwendung
EP0644769A4 (de) Biologisch aktive peptide mit n-terminalen substitutionen.
EP0889903A4 (de) Antimikrobielle peptide mit einem breiten wirkungsspektrum, die ein tryptophan-triplett enthalten, und methoden für ihre verwendung.
CA2204151A1 (en) Cdna encoding a bmp type ii receptor
DE69808717D1 (de) Atriale natriuretische peptide (anp) als zusatzstoff für peritonealdialyse
EP0372503A3 (de) Antikoagulierende Peptide
ZA966489B (en) New protein human MP52 Arg.
AUPO029096A0 (en) Npy y2 agonists
NO974713L (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
TR199902605T2 (xx) Fibrinojenin azalt�lma y�ntemleri.
DE69415548D1 (de) Haemoregulatorische penta-oder hexapeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0728147

Country of ref document: EP